REGENERON PHARMACEUTICALS (RGO.DE) Stock Fundamental Analysis

FRA:RGO • US75886F1075

675.6 EUR
+12.4 (+1.87%)
Last: Feb 13, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

7

RGO gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 78 industry peers in the Biotechnology industry. RGO scores excellent points on both the profitability and health parts. This is a solid base for a good stock. RGO is not valued too expensively and it also shows a decent growth rate. This makes RGO very considerable for quality investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • RGO had positive earnings in the past year.
  • In the past year RGO had a positive cash flow from operations.
  • In the past 5 years RGO has always been profitable.
  • In the past 5 years RGO always reported a positive cash flow from operatings.
RGO.DE Yearly Net Income VS EBIT VS OCF VS FCFRGO.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

1.2 Ratios

  • RGO has a Return On Assets of 11.11%. This is amongst the best in the industry. RGO outperforms 87.18% of its industry peers.
  • RGO has a Return On Equity of 14.41%. This is amongst the best in the industry. RGO outperforms 85.90% of its industry peers.
  • With an excellent Return On Invested Capital value of 7.54%, RGO belongs to the best of the industry, outperforming 88.46% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for RGO is below the industry average of 11.39%.
Industry RankSector Rank
ROA 11.11%
ROE 14.41%
ROIC 7.54%
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)8.87%
ROIC(5y)14.2%
RGO.DE Yearly ROA, ROE, ROICRGO.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • RGO's Profit Margin of 31.41% is amongst the best of the industry. RGO outperforms 88.46% of its industry peers.
  • RGO's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 27.02%, RGO belongs to the top of the industry, outperforming 87.18% of the companies in the same industry.
  • RGO's Operating Margin has declined in the last couple of years.
  • RGO has a Gross Margin of 86.56%. This is amongst the best in the industry. RGO outperforms 80.77% of its industry peers.
  • In the last couple of years the Gross Margin of RGO has remained more or less at the same level.
Industry RankSector Rank
OM 27.02%
PM (TTM) 31.41%
GM 86.56%
OM growth 3Y-14.45%
OM growth 5Y-8.44%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.04%
GM growth 5Y-0.06%
RGO.DE Yearly Profit, Operating, Gross MarginsRGO.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), RGO is creating some value.
  • RGO has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, RGO has less shares outstanding
  • Compared to 1 year ago, RGO has an improved debt to assets ratio.
RGO.DE Yearly Shares OutstandingRGO.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
RGO.DE Yearly Total Debt VS Total AssetsRGO.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • RGO has an Altman-Z score of 7.76. This indicates that RGO is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of RGO (7.76) is better than 83.33% of its industry peers.
  • RGO has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
  • The Debt to FCF ratio of RGO (0.72) is better than 88.46% of its industry peers.
  • RGO has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • RGO has a better Debt to Equity ratio (0.09) than 64.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.72
Altman-Z 7.76
ROIC/WACC0.9
WACC8.4%
RGO.DE Yearly LT Debt VS Equity VS FCFRGO.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.3 Liquidity

  • RGO has a Current Ratio of 4.13. This indicates that RGO is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 4.13, RGO is doing good in the industry, outperforming 76.92% of the companies in the same industry.
  • A Quick Ratio of 3.56 indicates that RGO has no problem at all paying its short term obligations.
  • RGO has a better Quick ratio (3.56) than 71.79% of its industry peers.
Industry RankSector Rank
Current Ratio 4.13
Quick Ratio 3.56
RGO.DE Yearly Current Assets VS Current LiabilitesRGO.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for RGO have decreased by -2.76% in the last year.
  • RGO shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.99% yearly.
  • RGO shows a small growth in Revenue. In the last year, the Revenue has grown by 0.99%.
  • The Revenue has been growing by 11.04% on average over the past years. This is quite good.
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%

3.2 Future

  • Based on estimates for the next years, RGO will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.00% on average per year.
  • Based on estimates for the next years, RGO will show a quite strong growth in Revenue. The Revenue will grow by 8.09% on average per year.
EPS Next Y4.68%
EPS Next 2Y11.02%
EPS Next 3Y11.23%
EPS Next 5Y11%
Revenue Next Year9.08%
Revenue Next 2Y9.41%
Revenue Next 3Y8.95%
Revenue Next 5Y8.09%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
RGO.DE Yearly Revenue VS EstimatesRGO.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
RGO.DE Yearly EPS VS EstimatesRGO.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20 40 60 80

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • RGO is valuated rather expensively with a Price/Earnings ratio of 18.00.
  • Compared to the rest of the industry, the Price/Earnings ratio of RGO indicates a rather cheap valuation: RGO is cheaper than 89.74% of the companies listed in the same industry.
  • RGO's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.16.
  • RGO is valuated rather expensively with a Price/Forward Earnings ratio of 17.20.
  • Based on the Price/Forward Earnings ratio, RGO is valued cheaper than 92.31% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of RGO to the average of the S&P500 Index (28.10), we can say RGO is valued slightly cheaper.
Industry RankSector Rank
PE 18
Fwd PE 17.2
RGO.DE Price Earnings VS Forward Price EarningsRGO.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RGO is valued cheaper than 84.62% of the companies in the same industry.
  • 87.18% of the companies in the same industry are more expensive than RGO, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 22.43
EV/EBITDA 12.98
RGO.DE Per share dataRGO.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200 250

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • RGO has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.85
PEG (5Y)2.57
EPS Next 2Y11.02%
EPS Next 3Y11.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.48%, RGO is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.47, RGO pays a better dividend. On top of this RGO pays more dividend than 94.87% of the companies listed in the same industry.
  • With a Dividend Yield of 0.48, RGO pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.48%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
RGO.DE Yearly Dividends per shareRGO.DE Yearly Dividends per shareYearly Dividends per share 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • RGO pays out 8.22% of its income as dividend. This is a sustainable payout ratio.
DP8.22%
EPS Next 2Y11.02%
EPS Next 3Y11.23%
RGO.DE Yearly Income VS Free CF VS DividendRGO.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B
RGO.DE Dividend Payout.RGO.DE Dividend Payout, showing the Payout Ratio.RGO.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

REGENERON PHARMACEUTICALS

FRA:RGO (2/13/2026, 7:00:00 PM)

675.6

+12.4 (+1.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-30
Earnings (Next)04-27
Inst Owners90.13%
Inst Owner ChangeN/A
Ins Owners1.95%
Ins Owner ChangeN/A
Market Cap71.42B
Revenue(TTM)14.34B
Net Income(TTM)4.50B
Analysts81.11
Price Target730.57 (8.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.48%
Yearly Dividend2.9
Dividend Growth(5Y)N/A
DP8.22%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.31%
Min EPS beat(2)5.66%
Max EPS beat(2)20.96%
EPS beat(4)3
Avg EPS beat(4)16.93%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.59%
EPS beat(12)10
Avg EPS beat(12)8.05%
EPS beat(16)13
Avg EPS beat(16)8.3%
Revenue beat(2)2
Avg Revenue beat(2)1.44%
Min Revenue beat(2)0.21%
Max Revenue beat(2)2.66%
Revenue beat(4)3
Avg Revenue beat(4)0.82%
Min Revenue beat(4)-9.32%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.06%
Revenue beat(12)8
Avg Revenue beat(12)0.91%
Revenue beat(16)12
Avg Revenue beat(16)1.57%
PT rev (1m)6.38%
PT rev (3m)-16.64%
EPS NQ rev (1m)-12.92%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.85%
EPS NY rev (3m)-2.33%
Revenue NQ rev (1m)-0.45%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.24%
Revenue NY rev (3m)5.93%
Valuation
Industry RankSector Rank
PE 18
Fwd PE 17.2
P/S 5.89
P/FCF 22.43
P/OCF 16.96
P/B 2.7
P/tB 2.82
EV/EBITDA 12.98
EPS(TTM)37.53
EY5.56%
EPS(NY)39.28
Fwd EY5.81%
FCF(TTM)30.12
FCFY4.46%
OCF(TTM)39.82
OCFY5.89%
SpS114.72
BVpS250.01
TBVpS239.95
PEG (NY)3.85
PEG (5Y)2.57
Graham Number459.47
Profitability
Industry RankSector Rank
ROA 11.11%
ROE 14.41%
ROCE 10.71%
ROIC 7.54%
ROICexc 23.05%
ROICexgc 25.78%
OM 27.02%
PM (TTM) 31.41%
GM 86.56%
FCFM 26.25%
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)8.87%
ROIC(5y)14.2%
ROICexc(3y)17.08%
ROICexc(5y)22.5%
ROICexgc(3y)18.5%
ROICexgc(5y)23.56%
ROCE(3y)12.6%
ROCE(5y)20.17%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y2.24%
ROICexc growth 3Y4.54%
ROICexc growth 5Y-0.03%
OM growth 3Y-14.45%
OM growth 5Y-8.44%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.04%
GM growth 5Y-0.06%
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.72
Debt/EBITDA 0.61
Cap/Depr 223.23%
Cap/Sales 8.46%
Interest Coverage 93.15
Cash Conversion 112.68%
Profit Quality 83.58%
Current Ratio 4.13
Quick Ratio 3.56
Altman-Z 7.76
F-Score5
WACC8.4%
ROIC/WACC0.9
Cap/Depr(3y)208.61%
Cap/Depr(5y)258.46%
Cap/Sales(3y)7.24%
Cap/Sales(5y)7.69%
Profit Quality(3y)85.52%
Profit Quality(5y)83.15%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
EPS Next Y4.68%
EPS Next 2Y11.02%
EPS Next 3Y11.23%
EPS Next 5Y11%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%
Revenue Next Year9.08%
Revenue Next 2Y9.41%
Revenue Next 3Y8.95%
Revenue Next 5Y8.09%
EBIT growth 1Y-8.13%
EBIT growth 3Y-9.64%
EBIT growth 5Y1.67%
EBIT Next Year12.49%
EBIT Next 3Y19.46%
EBIT Next 5Y10.58%
FCF growth 1Y6.39%
FCF growth 3Y3.48%
FCF growth 5Y13.45%
OCF growth 1Y12.63%
OCF growth 3Y-0.24%
OCF growth 5Y13.72%

REGENERON PHARMACEUTICALS / RGO.DE FAQ

Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?

ChartMill assigns a fundamental rating of 7 / 10 to RGO.DE.


Can you provide the valuation status for REGENERON PHARMACEUTICALS?

ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (RGO.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for REGENERON PHARMACEUTICALS?

REGENERON PHARMACEUTICALS (RGO.DE) has a profitability rating of 7 / 10.


What are the PE and PB ratios of REGENERON PHARMACEUTICALS (RGO.DE) stock?

The Price/Earnings (PE) ratio for REGENERON PHARMACEUTICALS (RGO.DE) is 18 and the Price/Book (PB) ratio is 2.7.


Can you provide the dividend sustainability for RGO stock?

The dividend rating of REGENERON PHARMACEUTICALS (RGO.DE) is 3 / 10 and the dividend payout ratio is 8.22%.